Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.

Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.

J Am Soc Nephrol. 2019 Jun;30(6):1096-1108. doi: 10.1681/ASN.2018101058. Epub 2019 May 13.

PMID:
31085679
2.

Cholestasis affects enteral tolerance and prospective weight gain in the NICU.

Niccum M, Khan MN, Middleton JP, Vergales BD, Syed S.

Clin Nutr ESPEN. 2019 Apr;30:119-125. doi: 10.1016/j.clnesp.2019.01.006. Epub 2019 Feb 4.

PMID:
30904211
3.

Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4.

Edmonston D, Morris JD, Middleton JP.

Adv Chronic Kidney Dis. 2018 Sep;25(5):454-467. doi: 10.1053/j.ackd.2018.08.010. Review.

PMID:
30309463
4.

Serum Potassium Levels and Risk of Sudden Cardiac Death Among Patients With Chronic Kidney Disease and Significant Coronary Artery Disease.

Pun PH, Goldstein BA, Gallis JA, Middleton JP, Svetkey LP.

Kidney Int Rep. 2017 Jul 17;2(6):1122-1131. doi: 10.1016/j.ekir.2017.07.001. eCollection 2017 Nov.

5.

Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk.

Pun PH, Middleton JP.

J Am Soc Nephrol. 2017 Dec;28(12):3441-3451. doi: 10.1681/ASN.2017060640. Epub 2017 Oct 9. Review.

6.

Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.

Middleton JP, Wolf M.

JAMA. 2017 Jan 10;317(2):139-141. doi: 10.1001/jama.2016.18631. No abstract available.

7.

Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial.

Pun PH, Abdalla S, Block GA, Chertow GM, Correa-Rotter R, Dehmel B, Dr├╝eke TB, Floege J, Goodman WG, Herzog CA, London GM, Mahaffey KW, Moe SM, Parfrey PS, Wheeler DC, Middleton JP.

Hemodial Int. 2016 Jul;20(3):421-31. doi: 10.1111/hdi.12382. Epub 2015 Nov 13.

8.

Magnetic Resonance Enterography Healing and Magnetic Resonance Enterography Remission Predicts Improved Outcome in Pediatric Crohn Disease.

Sauer CG, Middleton JP, McCracken C, Loewen J, Braithwaite K, Alazraki A, Martin DR, Kugathasan S.

J Pediatr Gastroenterol Nutr. 2016 Mar;62(3):378-83. doi: 10.1097/MPG.0000000000000976.

PMID:
26348683
9.

Clinical Outcomes in Dialysis Patients: Prospects for Improvement with Aldosterone Receptor Antagonists.

Suthar SD, Middleton JP.

Semin Dial. 2016 Jan-Feb;29(1):52-61. doi: 10.1111/sdi.12421. Epub 2015 Aug 4. Review.

PMID:
26242304
10.

The need for collaboration to improve cardiovascular outcomes in patients with CKD.

Middleton JP, Patel UD.

Adv Chronic Kidney Dis. 2014 Nov;21(6):456-9. doi: 10.1053/j.ackd.2014.08.007. Epub 2014 Oct 24. No abstract available.

PMID:
25443570
11.

Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study.

Pun PH, Hellkamp AS, Sanders GD, Middleton JP, Hammill SC, Al-Khalidi HR, Curtis LH, Fonarow GC, Al-Khatib SM.

Nephrol Dial Transplant. 2015 May;30(5):829-35. doi: 10.1093/ndt/gfu274. Epub 2014 Nov 17.

12.

Prescriptions for dietary sodium in patients with chronic kidney disease: how will this shake out?

Middleton JP, Lehrich RW.

Kidney Int. 2014 Sep;86(3):457-9. doi: 10.1038/ki.2014.124.

13.

Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.

Middleton JP, Wiener RC, Barnes BH, Gurka MJ, DeBoer MD.

Clin Pediatr (Phila). 2014 Dec;53(14):1318-25. doi: 10.1177/0009922813520072. Epub 2014 Jan 28. Review. No abstract available.

14.

IgG4-related tubulointerstitial nephritis associated with chronic lymphocytic leukemia.

Malone AF, Sparks MA, Howell DN, Middleton JP, Smith SR, Lehrich RW.

J Nephrol. 2013 Nov-Dec;26(6):1195-8. doi: 10.5301/jn.5000298. Epub 2013 Nov 26.

PMID:
24284523
15.

Vitamin D status and bone mineral density in African American children with Crohn disease.

Middleton JP, Bhagavathula AP, Gaye B, Alvarez JA, Huang CS, Sauer CG, Tenjarla G, Schoen BT, Kumar A, Prasad M, Okou DT, Ifeadike WC, Dhere TA, Conneely KN, Ziegler TR, Tangpricha V, Kugathasan S.

J Pediatr Gastroenterol Nutr. 2013 Nov;57(5):587-93. doi: 10.1097/MPG.0b013e31829e0b89.

16.

Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.

Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O.

Oncologist. 2013;18(3):273-80. doi: 10.1634/theoncologist.2012-0339. Epub 2013 Mar 13.

17.

Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients.

Pun PH, Horton JR, Middleton JP.

Clin J Am Soc Nephrol. 2013 May;8(5):797-803. doi: 10.2215/CJN.10000912. Epub 2013 Jan 31.

18.

Sudden cardiac arrest in ESRD patients.

Surana SP, Pun PH, Keithi-Reddy SR, Spiegel SM, Middleton JP, Singh AK.

Clin Nephrol. 2014 Feb;81(2):121-31. doi: 10.5414/CN107667.

PMID:
23149247
19.

A pilot study using an implantable device to characterize cardiac arrhythmias in hemodialysis patients: implications for future research.

Pun PH, Schumm D, Sanders GD, Hickey D, Middleton JP, Clapp-Channing N, Al-Khatib SM.

Ann Noninvasive Electrocardiol. 2012 Apr;17(2):159. doi: 10.1111/j.1542-474X.2012.00491.x. No abstract available.

PMID:
22537338
20.

Comparison of magnetic resonance enterography with endoscopy, histopathology, and laboratory evaluation in pediatric Crohn disease.

Sauer CG, Middleton JP, Alazraki A, Udayasankar UK, Kalb B, Applegate KE, Martin DR, Kugathasan S.

J Pediatr Gastroenterol Nutr. 2012 Aug;55(2):178-84. doi: 10.1097/MPG.0b013e3182598465.

PMID:
22513710
21.

Sudden cardiac death in hemodialysis patients: a comprehensive care approach to reduce risk.

Pun PH, Middleton JP.

Blood Purif. 2012;33(1-3):183-9. doi: 10.1159/000334154. Epub 2012 Jan 20. Review.

22.

Prehypertension and chronic kidney disease: the ox or the plow?

Middleton JP, Crowley SD.

Kidney Int. 2012 Feb;81(3):229-32. doi: 10.1038/ki.2011.393.

23.

Improving ascertainment of sudden cardiac death in patients with end stage renal disease.

Pun PH, Herzog CA, Middleton JP.

Clin J Am Soc Nephrol. 2012 Jan;7(1):116-22. doi: 10.2215/CJN.02820311. Epub 2011 Nov 10.

24.

Clinical trial of focal segmental glomerulosclerosis in children and young adults.

Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Hogan SL, Middleton JP, Vehaskari VM, Flynn PA, Powell LM, Vento SM, McMahan JL, Siegel N, D'Agati VD, Friedman AL.

Kidney Int. 2011 Oct;80(8):868-78. doi: 10.1038/ki.2011.195. Epub 2011 Jul 6.

25.

Predisposition to arrhythmias: electrolytes, uremic fibrosis, other factors.

Middleton JP.

Semin Dial. 2011 May-Jun;24(3):287-9. doi: 10.1111/j.1525-139X.2011.00866.x. Epub 2011 May 12. No abstract available.

PMID:
21564301
26.

Remobilization of residual non-aqueous phase liquid in porous media by freeze-thaw cycles.

Singh K, Niven RK, Senden TJ, Turner ML, Sheppard AP, Middleton JP, Knackstedt MA.

Environ Sci Technol. 2011 Apr 15;45(8):3473-8. doi: 10.1021/es200151g. Epub 2011 Mar 28.

PMID:
21438639
27.

Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life.

Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middleton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL.

Kidney Int. 2011 Mar;79(6):678-685. doi: 10.1038/ki.2010.485. Epub 2010 Dec 22.

28.

Modifiable risk factors associated with sudden cardiac arrest within hemodialysis clinics.

Pun PH, Lehrich RW, Honeycutt EF, Herzog CA, Middleton JP.

Kidney Int. 2011 Jan;79(2):218-27. doi: 10.1038/ki.2010.315. Epub 2010 Sep 1.

29.

Hypertension, chronic kidney disease, and the development of cardiovascular risk: a joint primacy.

Middleton JP, Pun PH.

Kidney Int. 2010 May;77(9):753-5. doi: 10.1038/ki.2010.19.

30.

CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.

Bhatnagar V, Garcia EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS; AASK Study Investigators.

Am J Nephrol. 2010;31(2):95-103. doi: 10.1159/000258688. Epub 2009 Nov 12.

31.

Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease.

Pun PH, Smarz TR, Honeycutt EF, Shaw LK, Al-Khatib SM, Middleton JP.

Kidney Int. 2009 Sep;76(6):652-8. doi: 10.1038/ki.2009.219. Epub 2009 Jun 17.

32.

G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions.

Bhatnagar V, O'Connor DT, Brophy VH, Schork NJ, Richard E, Salem RM, Nievergelt CM, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS; AASK Study Investigators.

Am J Hypertens. 2009 Mar;22(3):332-8. doi: 10.1038/ajh.2008.341. Epub 2009 Jan 1.

33.

Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients.

Li Y, Friedman JY, O'Neal BF, Hohenboken MJ, Griffiths RI, Stryjewski ME, Middleton JP, Schulman KA, Inrig JK, Fowler VG Jr, Reed SD.

Clin J Am Soc Nephrol. 2009 Feb;4(2):428-34. doi: 10.2215/CJN.03760708. Epub 2008 Dec 31.

34.

Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.

Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, Smith DW, Bakris GL, Middleton JP, Norris KC, Wright JT, Cheek D, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS.

J Hypertens. 2007 Oct;25(10):2082-92.

35.

Predictors of survival after cardiac arrest in outpatient hemodialysis clinics.

Pun PH, Lehrich RW, Smith SR, Middleton JP.

Clin J Am Soc Nephrol. 2007 May;2(3):491-500. Epub 2007 Feb 14.

36.

Automated external defibrillators and survival from cardiac arrest in the outpatient hemodialysis clinic.

Lehrich RW, Pun PH, Tanenbaum ND, Smith SR, Middleton JP.

J Am Soc Nephrol. 2007 Jan;18(1):312-20. Epub 2006 Dec 6.

37.

Unexpected role of TRPC6 channel in familial nephrotic syndrome: does it have clinical implications?

Winn MP, Daskalakis N, Spurney RF, Middleton JP.

J Am Soc Nephrol. 2006 Feb;17(2):378-87. Epub 2006 Jan 5. Review. No abstract available.

38.

Lambda light chain deposition disease in a renal allograft.

Tanenbaum ND, Howell DN, Middleton JP, Spurney RF.

Transplant Proc. 2005 Dec;37(10):4289-92.

PMID:
16387099
39.

Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.

Dember LM, Kaufman JS, Beck GJ, Dixon BS, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kusek JW, Lawson JH, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group.

Clin Trials. 2005;2(5):413-22.

PMID:
16317810
40.

Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.

Dixon BS, Beck GJ, Dember LM, Depner TA, Gassman JJ, Greene T, Himmelfarb J, Hunsicker LG, Kaufman JS, Lawson JH, Meyers CM, Middleton JP, Radeva M, Schwab SJ, Whiting JF, Feldman HI; DAC Study Group.

Clin Trials. 2005;2(5):400-12.

PMID:
16317809
41.

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group.

JAMA. 2002 Nov 20;288(19):2421-31. Erratum in: JAMA. 2006 Jun 21;295(23):2726.

PMID:
12435255
42.

Improving survival of octogenarian patients selected for haemodialysis.

Peri UN, Fenves AZ, Middleton JP.

Nephrol Dial Transplant. 2001 Nov;16(11):2201-6.

PMID:
11682668
43.

Ischemic disease of the kidney: how and why to consider revascularization.

Middleton JP.

J Nephrol. 1998 May-Jun;11(3):123-36. Review.

PMID:
9650120
44.

Direct regulation of the Na,K pump by signal transduction mechanisms.

Middleton JP.

Miner Electrolyte Metab. 1996;22(5-6):293-302. Review.

PMID:
8933500
45.

Modulation of thromboxane receptor activation in rat glomerular mesangial cells.

Spurney RF, Middleton JP, Raymond JR, Coffman TM.

Am J Physiol. 1994 Sep;267(3 Pt 2):F467-78.

PMID:
8092261
46.

Aluminum-induced DNA synthesis in osteoblasts: mediation by a G-protein coupled cation sensing mechanism.

Quarles LD, Hartle JE 2nd, Middleton JP, Zhang J, Arthur JM, Raymond JR.

J Cell Biochem. 1994 Sep;56(1):106-17.

PMID:
7806584
47.

Adenosine triphosphate activates ion permeabilities in biliary epithelial cells.

McGill JM, Basavappa S, Mangel AW, Shimokura GH, Middleton JP, Fitz JG.

Gastroenterology. 1994 Jul;107(1):236-43.

PMID:
8020667
48.

Regulation of cation channels in liver cells by intracellular calcium and protein kinase C.

Fitz JG, Sostman AH, Middleton JP.

Am J Physiol. 1994 Apr;266(4 Pt 1):G677-84.

PMID:
7513961
49.

Heterogeneity of protein kinase C-mediated rapid regulation of Na/K-ATPase in kidney epithelial cells.

Middleton JP, Khan WA, Collinsworth G, Hannun YA, Medford RM.

J Biol Chem. 1993 Jul 25;268(21):15958-64.

50.

Supplemental Content

Loading ...
Support Center